RXRX 8-K
Recursion Pharmaceuticals, Inc. (RXRX)
8-K
2024-06-07
For: 2024-06-03
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2024
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip code)
(385 ) 269 - 0203
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
Recursion Pharmaceuticals, Inc. (the “Company”) held its 2024 annual meeting of stockholders (“Annual Meeting”) on June 3, 2024.
At the Annual Meeting, the Company’s stockholders voted on the following proposals, each of which is described in more detail in the Company’s definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2024 (the “Proxy Statement”):
Proposal 1: The stockholders elected as Class III directors the two individuals listed below to serve until the Company’s 2027 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows:
| Nominee | For | Withheld | Broker Non-Votes | |||||||||||||||||
| Blake Borgeson, Ph.D. | 165,914,956 | 26,093,759 | 0 | |||||||||||||||||
| Dean Y. Li, M.D., Ph.D. | 166,211,058 | 25,797,657 | 0 | |||||||||||||||||
Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 188,317,831 | 2,887,180 | 803,704 | 0 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on June 7, 2024.
| RECURSION PHARMACEUTICALS, INC. | ||||||||
| By: | /s/ Nathan Hatfield | |||||||
| Nathan Hatfield | ||||||||
Chief Legal Officer | ||||||||